{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:27:23Z","timestamp":1793114843229,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ijantimicag.2019.07.003","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T23:25:34Z","timestamp":1562369134000},"page":"790-797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis"],"prefix":"10.1016","volume":"54","author":[{"given":"Chi Phuong","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuc Nguyen","family":"Dan Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Bruggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"ten Oever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kolwijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy M.M.","family":"Adang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiman F.L.","family":"Wertheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijantimicag.2019.07.003_bib0001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cmi.2016.09.003","article-title":"Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States","volume":"23","author":"Bartsch","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.ijantimicag.2019.07.003_bib0002","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0003","series-title":"Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands","author":"Ir","year":"2017"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0004","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0005","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.00135-13","article-title":"Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"57","author":"Retamar","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0006","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2019.07.003_bib0007","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dkl043","article-title":"Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England","volume":"57","author":"Livermore","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0008","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime\u2013avibactam versus imipenem\u2013cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Kreidly","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0009","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0010","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Eckmann","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0011","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","year":"2011"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0012","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses n.d. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp(accessed March 20, 2018)."},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0013","unstructured":"National Heart Lung and Blood Institute. Quality Assessment Tool for Case Series Studies n.d.https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools(accessed February 20, 2018)."},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13756-017-0264-2","volume":"6","author":"Prabhu","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02447-16","article-title":"Molecular beta-lactamase characterization of aerobic gram-negative pathogens recovered from patients enrolled in the susceptible and resistant subsets","volume":"61","author":"Mendes","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0016","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: A pooled analysis of Phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0017","series-title":"Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg (Dutch)","author":"Hakkaart-van Roijen","year":"2016"},{"issue":"6","key":"10.1016\/j.ijantimicag.2019.07.003_bib0018","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1524-4733.2010.00736.x","article-title":"Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis","volume":"13","author":"Boersma","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0019","series-title":"Guideline for economic evaluations in healthcare","year":"2016"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0020","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"66","author":"Virgincar","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0021","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3906\/sag-1506-157","article-title":"Treatment efficacy and superinfection rates in complicated urinary tract infections treated with ertapenem or piperacillin tazobactam","volume":"46","author":"Dizbay","year":"2016","journal-title":"Turkish J Med Sci"},{"issue":"6","key":"10.1016\/j.ijantimicag.2019.07.003_bib0022","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":"Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-\u03b2-lactamase-producing Escherichia coli and Klebsiella species","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0023","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1128\/AAC.01450-09","article-title":"Worldwide experience with the use of doripenem against extended-spectrum- \u03b2-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: Analysis of six phase 3 clinical studies","volume":"54","author":"Kaniga","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0024","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1128\/AAC.01173-15","article-title":"\u03b2-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates","volume":"60","author":"Stone","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0025","first-page":"1","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"17","author":"Song","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0026","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijantimicag.2016.12.017","article-title":"Role of piperacillin\/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"49","author":"Yoon","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0027","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijantimicag.2017.09.013","article-title":"Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing enterobacteriaceae","volume":"51","author":"Kim","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0028","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejim.2017.10.014","article-title":"Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae in an Italian Internal Medicine ward","volume":"48","author":"Meini","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0029","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijantimicag.2018.04.001","article-title":"Molecular \u03b2-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resist","volume":"52","author":"Mendes","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0030","first-page":"1","article-title":"The relevance of ESBL producing isolates in patients surgically treated for acute appendicitis","volume":"59","author":"Gupta","year":"2011","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0031","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QCO.0000000000000493","article-title":"Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections","volume":"31","author":"Tumbarello","year":"2018","journal-title":"Curr Opin Infect Dis"},{"issue":"Supple:335","key":"10.1016\/j.ijantimicag.2019.07.003_bib0032","article-title":"Antibiotic choice for intra-abdominal infections due to ampc betalactamase-producing organisms","volume":"46","author":"Chang","year":"2018","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.ijantimicag.2019.07.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01917-17","article-title":"Point-Counterpoint: piperacillin-tazobactam should be used to treat infections with extended-spectrum-beta-lactamase-positive organisms","volume":"56","author":"Schuetz","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0034","article-title":"The MERINO trial: piperacillin-tazobactam versus meropenem for the definitive treatment of bloodstream infections caused by third-generation cephalosporin non-susceptible Escherichia coli or Klebsiella spp.: an international multi-centre open label study","author":"Harris","year":"2018","journal-title":"European Congress of Clinical Microbiology and Infectious Disease"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0035","unstructured":"(SWAB) SWA. National Antibiotics Booklet n.d.https:\/\/swabid.nl\/therapie(accessed July 3, 2018)."},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0036","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12879-017-2408-7","article-title":"Cost-effectiveness of ceftolozane\/tazobactam compared with piperacillin\/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections","volume":"17","author":"Kauf","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0037","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00019053-200119010-00006","article-title":"Cost efficacy of tazobactam\/piperacillin versus imipenem\/cilastatin in the treatment of intra-abdominal infection","volume":"19","author":"Dietrich","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0038","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10198-011-0296-0","article-title":"Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin\/tazobactam","volume":"13","author":"Edwards","year":"2012","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0039","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40258-015-0162-9","article-title":"Impact of a dynamic microbiological environment on the clinical efficacy of ertapenem and piperacillin\/tazobactam in the treatment of complicated community-acquired intra-abdominal infection in Spain: a cost-consequence analysis","volume":"13","author":"Grau","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ijantimicag.2019.07.003_bib0040","first-page":"1","article-title":"Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis","volume":"16","author":"Horhat","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T16:06:57Z","timestamp":1574784417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919301839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0924857919301839"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.07.003","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}